OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective. DESIGN: This study was cross-sectional and experimental in design. METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)). RESULTS: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05). CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.
OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective. DESIGN: This study was cross-sectional and experimental in design. METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)). RESULTS:Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05). CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.
Authors: Zeinab Sarem; Christiane Bumke-Vogt; Ayman M Mahmoud; Biruhalem Assefa; Martin O Weickert; Aikatarini Adamidou; Volker Bähr; Jan Frystyk; Matthias Möhlig; Joachim Spranger; Stefanie Lieske; Andreas L Birkenfeld; Andreas F H Pfeiffer; Ayman M Arafat Journal: J Clin Endocrinol Metab Date: 2017-09-01 Impact factor: 5.958
Authors: Tobias Hebel; Kristina Eisinger; Markus Neumeier; Lisa Rein-Fischboeck; Rebekka Pohl; Elisabeth M Meier; Alfred Boettcher; Stanley C Froehner; Marvin E Adams; Gerhard Liebisch; Sabrina Krautbauer; Christa Buechler Journal: Biochim Biophys Acta Date: 2015-01-24
Authors: Christian von Loeffelholz; Stefanie Lieske; Frank Neuschäfer-Rube; Diana M Willmes; Nathanael Raschzok; Igor M Sauer; Jörg König; Martin F Fromm; Paul Horn; Antonios Chatzigeorgiou; Andrea Pathe-Neuschäfer-Rube; Jens Jordan; Andreas F H Pfeiffer; Geltrude Mingrone; Stefan R Bornstein; Peter Stroehle; Christoph Harms; F Thomas Wunderlich; Stephen L Helfand; Michel Bernier; Rafael de Cabo; Gerald I Shulman; Triantafyllos Chavakis; Gerhard P Püschel; Andreas L Birkenfeld Journal: Hepatology Date: 2017-06-26 Impact factor: 17.425
Authors: Olga Pivovarova; Christian von Loeffelholz; Iryna Ilkavets; Carsten Sticht; Sergei Zhuk; Veronica Murahovschi; Sonja Lukowski; Stephanie Döcke; Jennifer Kriebel; Tonia de las Heras Gala; Anna Malashicheva; Anna Kostareva; Johan F Lock; Martin Stockmann; Harald Grallert; Norbert Gretz; Steven Dooley; Andreas F H Pfeiffer; Natalia Rudovich Journal: Cell Cycle Date: 2015-05-06 Impact factor: 4.534
Authors: Erifili Hatziagelaki; Christian Herder; Anastasia Tsiavou; Tom Teichert; Athina Chounta; Peter Nowotny; Giovanni Pacini; George Dimitriadis; Michael Roden Journal: PLoS One Date: 2015-05-01 Impact factor: 3.240
Authors: Nanda Gruben; Marcela Aparicio Vergara; Niels J Kloosterhuis; Henk van der Molen; Stefan Stoelwinder; Sameh Youssef; Alain de Bruin; Dianne J Delsing; Jan Albert Kuivenhoven; Bart van de Sluis; Marten H Hofker; Debby P Y Koonen Journal: PLoS One Date: 2014-04-29 Impact factor: 3.240